A SARS-CoV-2 nucleocapsid ELISA represents a low-cost alternative to lateral flow testing for community screening in LMI countries.
Humbert MV, Opurum PC, Brendish NJ, Poole S, He P, Katis I, Quaye J, Bediako Y, Duriez PJ, Eason RW, Sones C, Quaye O, Awandare GA, Christodoulides M, Clark TW, Quashie PK, McCormick CJ.
Humbert MV, et al. Among authors: eason rw.
J Infect. 2022 Jan;84(1):48-55. doi: 10.1016/j.jinf.2021.08.049. Epub 2021 Oct 1.
J Infect. 2022.
PMID: 34606784
Free PMC article.